These observations may point toward a role of CCL21 in the anti-tumor immune response related to the proportion and type of immune cells present in or around the tumor in EWS patients; this has been observed in other tumors including breast cancer and melanoma [25–27]. This evidence concerns the gene CCL21 and breast carcinoma.